title: Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
authors.forename: L
authors.initials: L
authors.lastname: Adès
authors.forename: V
authors.initials: V
authors.lastname: Eclache
authors.forename: C
authors.initials: C
authors.lastname: Gardin
authors.forename: S
authors.initials: S
authors.lastname: Boehrer
authors.forename: G
authors.initials: G
authors.lastname: Leroux
authors.forename: P
authors.initials: P
authors.lastname: Martiat
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D005260:Female; D017353:Gene Deletion; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide